A study involving more than 80,000 men followed for 10 years gives some important clues, but no final answers, on what patients with a diagnosis of prostate cancer should do. It’s long been a puzzle because prostate cancer is one of the most common and deadliest cancers for men, yet in many cases it’s so slow to grow that men die with, not from, prostate cancer.
Here’s the bottom line, which the researchers emphasized needs to be continued for an even longer time for its findings to be more authoritative:
At a median of 10 years, prostate-cancer–specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Surgery and radiotherapy were associated with lower incidences of disease progression and metastases than was active monitoring.